Resources

2 Resources for

requip

GlaxoSmithKline Bets Solzira Can Win Where Requip Failed: GlaxoSmithKline's announcement yesterday that it is submitting a new drug application for Solzira to the FDA for the treatment of Restless Legs Syndrome raises a question: What was wrong with its old treatment for RLS, Requip, launched only in 2005? The short answer is that it was...; Tags: Advertisement, Generic, GlaxoSmithKline Plc., Requip, GSK, Nielsen Monitor-Plus, Sales Strategy, Sales, Jim Edwards; Blog posts 2008-09-17
GlaxoSmithKline Bets Solzira Can Win Where Requip Failed: GlaxoSmithKline Bets Solzira Can Win Where Requip FailedRE: GlaxoSmithKline Bets Solzira Can Win Where Requip FailedA reader wrote this note to me:Just had to comment that I have been on requip for over a year now for severe restless leg syndrome, i threw up almost every night for a couple...; Tags: Requip, Solzira, GlaxoSmithKline Plc.; Discussion threads 2008-09-27

SmithKline Enters Requip Collaboration.(SkyePharma PLC and anti-Parkinson's Disease drug): SMITHKLINE BEECHAM has entered into a development and licensing agreement with SkyePharma PLC for a once-daily version of Requip ropinirole, SB's drug for Parkinson's disease. The collaboration will use SkyePharma's Geomatrix oral delivery techn SMITHKLINE BEECHAM has entered into a development and licensing...; Tags: Parkinson; Research articles 1999-09-20
SkyePharma PLC announces Once-Daily REQUIP(R) (ropinirole HCl) XL 24-Hour(TM) Extended-Release Tablets Accepted for Filing by U.S. FDA: Once-Daily REQUIPR ropinirole HCl XL 24-HourTM Extended-Release Tablets Accepted for Filing by U.S. FDA; Tags: FDA; Research articles 2007-04-13
Requip now has generic competitors: WASHINGTON -- The Food and Drug Administration last month approved the first generic versions of Requip GlaxoSmithKline PLC for treating moderate to severe restless leg syndrome. Ropinirole hydrochloride tablets were cleared in 0.25-, 0.5-, 1-, 2-, 3- and 4-mg dosages. "This generic drug approval is an example of the...; Tags: FDA, GlaxoSmithKline Plc., Mylan Pharmaceuticals Inc.; Research articles 2008-06-30

Skyepharma PLC Announces Regulatory Approval: FDA APPROVES REQUIP® XLTM, THE FIRST AND ONLY ORAL ONCE-DAILY NON-ERGOT DOPAMINE AGONIST FOR PARKINSON'S DISEASE Extended-Release Formulation Improved Symptoms in Patients Not Optimally Controlled with Levodopa and Reduced Patients'"Off" Time by Nearly Two Hours Per Day LONDON, UK, 16 June 2008 -- SkyePharma PLC (LSE: SKP) today...; Tags: Parkinson, patient; Research articles 2008-06-16
The New England Journal of Medicine publishes important Parkinson's Disease study; Results may change the way physicians treat the disease.: M2 PRESSWIRE-19 May 2000-SMITHKLINE BEECHAM: The New England Journal of Medicine publishes important Parkinson's Disease study; Results may change the way physicians treat the disease C1994-2000 M2 COMMUNICATIONS LTD RDATE:18052000 PHILADELPHIA, PA -- SmithKline Beecham's Requip ropinirole hydrochloride...; Tags: The New England Journal of Medicine; Research articles 2000-05-19